Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

8.365
+0.0650.78%
Volume:2.13M
Turnover:17.73M
Market Cap:8.80B
PE:-19.35
High:8.510
Open:8.295
Low:8.135
Close:8.300
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.84
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.432
ROE:-28.59%
ROA:-19.64%
PB:3.32
PE(LYR):-19.35
PS:7957.51

Loading ...

Ascletis Hits 5-week High on New Drug Applications for Obesity Treatment

Reuters
·
Jul 06

Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?

Simply Wall St.
·
Jul 06

ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection

Stock News
·
Jul 06

Ascletis Submits Two Obesity-drug IND Applications to US FDA for Asc36, Asc36_35 FDC Injections

Reuters
·
Jul 06

Ascletis Pharma - Submits Two Ind Applications to U.S. FDA for Obesity Treatment

THOMSON REUTERS
·
Jul 06

Ascletis Pharma Maintains Stable Share Capital Structure in June 2026; Public Float Above 25% Threshold

Bulletin Express
·
Jul 03

Ascletis Pharma Discloses 145,000-Share Buyback on 30 June; Outstanding Shares Steady at 1.06 Billion

Bulletin Express
·
Jun 30

Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock

Bulletin Express
·
Jun 30

Ascletis Pharma - to Use up to Hk$300 Mln for Share Repurchase

THOMSON REUTERS
·
Jun 30

Ascletis Pharma Plans up to Hk$300 Million Share Buyback Under Mandate

Reuters
·
Jun 30

Ascletis Revises Articles: Sets US$700,000 Authorised Capital, Enables Virtual Meetings and Three-Year Director Rotation

Bulletin Express
·
Jun 29

Ascletis Pharma Holds Annual Shareholder Meeting

Reuters
·
Jun 29

Ascletis Pharma Shareholders Approve Amended and Restated Bylaws

Reuters
·
Jun 29

ASCLETIS-B Shares Surge Over 7% on FDA IND Approval for ASC35 Phase I Study and GIC's Consistent Share Purchases

Stock News
·
Jun 29

Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion

Bulletin Express
·
Jun 26

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jun 26

Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?

Simply Wall St.
·
Jun 24

ASCLETIS PHARMA CONDUCTS HK$2.02 MILLION SHARE BUYBACK

Stock News
·
Jun 24

Ascletis Pharma Gets US FDA Nod for Obesity Drug Trial

MT Newswires Live
·
Jun 23

ASCLETIS-B Receives FDA Clearance for Phase I Study of Its Monthly Subcutaneous GLP-1R/GIPR Dual Agonist Peptide ASC35 in Obesity

Stock News
·
Jun 23